Phase 1 Study Shows Promising Results for Zanubrutinib Plus Lenalidomide in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

A phase 1 multicenter study, BGB-3111-110, evaluated the combination therapy of zanubrutinib and lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). The study, published in Blood Advances, found no dose-limiting toxicities, with the recommended phase 2 dose for lenalidomide being 25 mg once daily when combined with zanubrutinib 160 mg twice daily. The most common grade ≥3 treatment-emergent adverse events were decreased neutrophil count (58%) and decreased white blood cell count (29%). This research provides insights into a potential new treatment option for patients with this aggressive lymphoma.